Progyny, Inc. (NASDAQ:PGNY) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Progyny, Inc. (NASDAQ:PGNY) have been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $27.3333.

Several research analysts have weighed in on PGNY shares. Canaccord Genuity Group increased their price objective on Progyny from $23.00 to $26.00 and gave the stock a “hold” rating in a research report on Monday, November 17th. KeyCorp upgraded shares of Progyny from a “sector weight” rating to an “overweight” rating and set a $30.00 price objective for the company in a research note on Tuesday, November 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $28.00 target price (up from $26.00) on shares of Progyny in a report on Friday, August 8th. Raymond James Financial set a $28.00 price target on Progyny in a research note on Friday, August 8th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Progyny in a research note on Wednesday, October 8th.

Insider Buying and Selling

In other Progyny news, CFO Mark S. Livingston sold 21,303 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $25.50, for a total transaction of $543,226.50. Following the sale, the chief financial officer directly owned 48,358 shares in the company, valued at $1,233,129. This represents a 30.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Allison Swartz sold 2,398 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $22.96, for a total transaction of $55,058.08. Following the sale, the executive vice president directly owned 79,697 shares of the company’s stock, valued at approximately $1,829,843.12. This trade represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 26,698 shares of company stock valued at $667,437 over the last quarter. 9.40% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PGNY. Nordea Investment Management AB boosted its position in Progyny by 0.6% in the second quarter. Nordea Investment Management AB now owns 183,362 shares of the company’s stock valued at $4,052,000 after buying an additional 1,140 shares in the last quarter. Voya Investment Management LLC lifted its stake in shares of Progyny by 258.2% in the 1st quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock valued at $4,144,000 after acquiring an additional 133,703 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Progyny by 7.5% in the 1st quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock valued at $29,107,000 after acquiring an additional 90,367 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Progyny by 243.6% during the 1st quarter. Acadian Asset Management LLC now owns 205,650 shares of the company’s stock valued at $4,589,000 after acquiring an additional 145,802 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd grew its position in Progyny by 88.0% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 56,196 shares of the company’s stock worth $1,236,000 after acquiring an additional 26,310 shares during the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Price Performance

Shares of PGNY opened at $26.33 on Tuesday. The firm has a market capitalization of $2.27 billion, a PE ratio of 41.79, a PEG ratio of 2.04 and a beta of 1.29. The company’s 50-day moving average is $21.37 and its 200-day moving average is $22.00. Progyny has a fifty-two week low of $13.86 and a fifty-two week high of $27.25.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.06. Progyny had a net margin of 4.46% and a return on equity of 10.71%. The business had revenue of $313.35 million for the quarter, compared to analyst estimates of $299.23 million. During the same quarter in the prior year, the business earned $0.11 EPS. Progyny’s quarterly revenue was up 9.3% on a year-over-year basis. Progyny has set its FY 2025 guidance at 1.790-1.820 EPS. Q4 2025 guidance at 0.370-0.400 EPS. Analysts predict that Progyny will post 0.6 earnings per share for the current fiscal year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.